Vivace Therapeutics Inc. - Company Profile

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

...and LF Investment in the round.Vivace picks up the pace with series CBoxer Capital led Vivace Therapeutics Inc.’s...
...2D membrane retina-specificROR2 - Receptor tyrosine kinase-like orphan receptor 2YAP1 (YAP) - Yes-associated protein 1 Paul Bonanos Vivace Therapeutics Inc. MinervaX...

...a Regeneron Pharmaceutical Inc. board member since 1988; and SAB member Leonard Post, CSO at Vivace Therapeutics Inc....
...Inc. (NASDAQ:RTRX), San Diego, Calif. Sangamo Therapeutics Inc. (NASDAQ:SGMO), Richmond, Calif. Stanford University, Stanford, Calif. Vivace Therapeutics Inc....

Breaking up Hippo to tame proliferation

...challenge has been that there’s no molecule target,” said Sofie Qiao, President and CEO of Vivace Therapeutics Inc....
...I think most of the challenge has been that there’s no molecule target.” Sofie Qiao, Vivace Therapeutics...
...sort out the function of each TEAD over the next couple of years.” Leonard Post, Vivace Therapeutics...

YAP off, YAP on

...has filed an undisclosed number of patent applications covering modulation of Hippo-YAP signaling. COMPANY PROFILE Vivace Therapeutics Inc....
...Darmstadt, Germany Reliance Life Sciences, Rabale, India University of California San Diego, La Jolla, Calif. Vivace Therapeutics Inc....
...“The Hippo pathway kinases LATS1/2 suppress cancer immunity.” Cell (2016) Michael Leviten, Senior Writer Cancer Research UK Merck KGaA UCSF Vivace Therapeutics Inc. Large...

Platelets YAP at cancer

...that are addicted to the pathway being turned on based on genetic mutations.” Leonard Post, Vivace Therapeutics...
...said Sood. According to BioCentury, no companies have disclosed compounds targeting YAP1 directly. In June, Vivace Therapeutics Inc....
...Institutes of Health (NIH), Bethesda, Md. University of Texas MD Anderson Cancer Center, Houston, Texas Vivace Therapeutics Inc....

Vivace Therapeutics Inc. , Orinda, Calif. Business: Cancer Date completed: 2015-01-20 Type: Venture financing Raised: $5.1 million Investor: Not disclosed Note: The company raised $5.1 million, according to an SEC filing. WIR Staff cancer...